Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Sep 2, 2026, 15:41Nour Al-Mozain: Rethinking the Role of Cold-Stored Platelets
-
Sep 2, 2026, 15:39Fahad Alshehri: Are All Platelets Created Equal?
-
Sep 2, 2026, 15:09Kim Cook: Bringing Rare Blood Cancers Into the Conversation
-
Sep 2, 2026, 15:08Anupriya Ak: Blood Groups and Transfusion Compatibility
-
Sep 2, 2026, 14:51Amir Hesam Karbakhsh: The Science Behind Platelet-Rich Plasma Preparation
-
Sep 2, 2026, 14:38Brandi Littles Kelly: Raising ITP Awareness Through a Family’s Journey
-
Sep 2, 2026, 14:36Sangita Saha: Hemolysis in Hemodialysis – Causes, Prevention, Patient Safety
-
Sep 2, 2026, 14:31David Smadja: A New School Year, A Stronger Hematology Team
-
Sep 2, 2026, 14:28Khaled Musallam: The 5th MENA Congress for Rare Diseases Is Coming to Abu Dhabi